5113
Pharmacoeconomics study of canakinumab in patients with cryopyrin-associated periodic syndromes (caps)
In this study we conducted pharmacoeconomic assessment of the use of canakinumab in patients with cryopyrin-associated periodic syndromes (CAPS) versus the symptomatic treatment alone. Incidence of remission in the treatment group was selected as the efficacy endpoint, and superior efficacy of canakinumab was demonstrated in the treatment group as compared to the symptomatic treatment. Based on cost-effectiveness analysis, it was determined that canakinumab treatment required considerable expenses; however, due to the small number of patients the impact on overall budget will be insignificant. It should also be noted that the treatment with this medicinal product will help reduce the costs of out-patient and policlinic care, in-patient medical care, as well as administration-related and complications management costs.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
A.Y. Kulikov, A.A. Pochuprina Pharmacoeconomics study of canakinumab in patients with cryopyrin-associated periodic syndromes (caps) // Pharmacoeconomics: theory and practice. - 2015. - Vol.3, №2. - P.51-53 DOI: https://doi.org/10.30809/phe.2.2015.6
Comments0